 | |
| Combination of | |
|---|---|
| Phentermine | Appetite suppressant/stimulant of the amphetamine and phenethylamine class |
| Topiramate | Anticonvulsant (extended release formulation is used) |
| Clinical data | |
| Pronunciation | /kjuːsɪˈmiːə/ kew-sim-EE-ə |
| Trade names | Qsymia, QSIVA® |
| AHFS/Drugs.com | Professional Drug Facts |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| (verify) | |
Phentermine/topiramate, sold under the brand names Qsymia or QSIVA, is a combination drug of phentermine and topiramate used to treat obesity.[1][2] It is used together with dietary changes and exercise.[3] If less than 3% weight loss is seen after 3 months it is recommended the medication be stopped.[3] The weight loss is modest.[3] Effects on heart related health problems or death is unclear.[3]
Common side effects include tingling, dizziness, trouble sleeping, and constipation.[3] Serious side effects may include suicide, abuse.[3] Use is not recommended during pregnancy.[1] Phentermine is a stimulant and appetite suppressant.[3] Topiramate is an anticonvulsant that has weight loss side effects.[3] The exact mechanism of action for both drugs is unknown.[3]
Phentermine/topiramate was approved for medical use in the United States in 2012.[3] In October 2012, approval was denied in Europe, due to concerns regarding safety.[4][5][6] It was approved in 2024 in Poland and all of Scandinavia.[2]
- ^ a b "Phentermine and topiramate Uses, Side Effects & Warnings". Drugs.com. Retrieved 13 April 2019.
- ^ a b "VIVUS Announces Commercialization of QSIVA in Sweden, Denmark, Finland, Iceland, Norway, and Poland". vivus.com. 7 October 2024. Retrieved 22 October 2024.
- ^ a b c d e f g h i j "DailyMed - Qsymia - phentermine and topiramate capsule, extended release". dailymed.nlm.nih.gov. Retrieved 13 April 2019.
- ^ "www.ema.europa.eu" (PDF). Archived from the original (PDF) on 21 December 2014.
- ^ Siebenhofer A, Winterholer S, Jeitler K, Horvath K, Berghold A, Krenn C, et al. (January 2021). "Long-term effects of weight-reducing drugs in people with hypertension". The Cochrane Database of Systematic Reviews. 1 (1): CD007654. doi:10.1002/14651858.CD007654.pub5. PMC 8094237. PMID 33454957.
- ^ "Qsiva". EMA. 13 June 2013.